Metsera has no products on the market, but its pipeline includes four programs in clinical development.
Five months after ending development of its own obesity treatment, Pfizer is accelerating its push into the rapidly growing field with a nearly $5 billion acquisition.
The COVID-19 vaccine and treatment maker said Monday that it will pay $47.50 in cash for each share of development-stage drugmaker Metsera. That represents a premium of more than 42% to Metsera’s closing price Friday.
Pfizer also could pay an additional $22.50 per share depending on how Metsera’s product pipeline develops.
Metsera Inc. has no products on the market, but its pipeline includes four programs in clinical development and one in mid-stage testing.
